TNSN08408A1 - PYRIDINE [3,4-b] PYRAZINONES - Google Patents

PYRIDINE [3,4-b] PYRAZINONES

Info

Publication number
TNSN08408A1
TNSN08408A1 TNP2008000408A TNSN08408A TNSN08408A1 TN SN08408 A1 TNSN08408 A1 TN SN08408A1 TN P2008000408 A TNP2008000408 A TN P2008000408A TN SN08408 A TNSN08408 A TN SN08408A TN SN08408 A1 TNSN08408 A1 TN SN08408A1
Authority
TN
Tunisia
Prior art keywords
pyrazinones
pyridine
compounds
methods
synthesis
Prior art date
Application number
TNP2008000408A
Other languages
English (en)
French (fr)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN08408A1 publication Critical patent/TNSN08408A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
TNP2008000408A 2006-04-21 2008-10-17 PYRIDINE [3,4-b] PYRAZINONES TNSN08408A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
TNSN08408A1 true TNSN08408A1 (fr) 2010-04-14

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000408A TNSN08408A1 (fr) 2006-04-21 2008-10-17 PYRIDINE [3,4-b] PYRAZINONES

Country Status (41)

Country Link
US (1) US7902195B2 (enExample)
EP (1) EP2013208B1 (enExample)
JP (1) JP4436892B2 (enExample)
KR (1) KR101061328B1 (enExample)
CN (1) CN101454320B (enExample)
AP (1) AP2408A (enExample)
AR (1) AR060525A1 (enExample)
AT (1) ATE513831T1 (enExample)
AU (1) AU2007242555B2 (enExample)
BR (1) BRPI0710658A2 (enExample)
CA (1) CA2649775C (enExample)
CR (1) CR10327A (enExample)
CU (1) CU23777B7 (enExample)
CY (1) CY1111739T1 (enExample)
DK (1) DK2013208T3 (enExample)
DO (1) DOP2007000080A (enExample)
EA (1) EA014919B1 (enExample)
EC (1) ECSP088803A (enExample)
ES (1) ES2366239T3 (enExample)
GT (1) GT200700035A (enExample)
HR (1) HRP20110539T1 (enExample)
IL (1) IL194591A (enExample)
MA (1) MA30352B1 (enExample)
ME (1) MEP23808A (enExample)
MX (1) MX2008012456A (enExample)
MY (1) MY148583A (enExample)
NL (1) NL2000583C2 (enExample)
NO (1) NO20084129L (enExample)
NZ (1) NZ571540A (enExample)
PA (1) PA8724201A1 (enExample)
PE (1) PE20080192A1 (enExample)
PL (1) PL2013208T3 (enExample)
RS (2) RS51885B (enExample)
SI (1) SI2013208T1 (enExample)
SV (1) SV2008003074A (enExample)
TN (1) TNSN08408A1 (enExample)
TW (1) TWI337609B (enExample)
UA (1) UA92637C2 (enExample)
UY (1) UY30291A1 (enExample)
WO (1) WO2007122466A1 (enExample)
ZA (1) ZA200808283B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
AU2007333115B2 (en) * 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
PT2247292T (pt) * 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
TW201020233A (en) * 2008-10-09 2010-06-01 Kyorin Seiyaku Kk Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
NZ599549A (en) * 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
PT2637664T (pt) 2010-10-15 2017-06-22 Gilead Sciences Inc Composições e métodos de tratamento de hipertensão pulmonar
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
WO2015150957A1 (en) 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
ES2924371T3 (es) 2015-06-17 2022-10-06 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
BR112018015191B1 (pt) 2016-02-23 2023-10-17 Pfizer Inc Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
MX2019015578A (es) * 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CA3094366A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivatives
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
AU656154B2 (en) * 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
TW274550B (enExample) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
EP1624900A4 (en) * 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
CA2529196A1 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
JP2009509923A (ja) * 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI

Also Published As

Publication number Publication date
HRP20110539T1 (hr) 2011-08-31
TWI337609B (en) 2011-02-21
SI2013208T1 (sl) 2011-09-30
NZ571540A (en) 2010-10-29
PA8724201A1 (es) 2009-08-26
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
CA2649775C (en) 2011-05-31
NO20084129L (no) 2008-10-29
AU2007242555A1 (en) 2007-11-01
US20070249615A1 (en) 2007-10-25
ES2366239T3 (es) 2011-10-18
CN101454320A (zh) 2009-06-10
MEP23808A (en) 2010-06-10
KR101061328B1 (ko) 2011-08-31
RS51885B (sr) 2012-02-29
AR060525A1 (es) 2008-06-25
UY30291A1 (es) 2007-11-30
BRPI0710658A2 (pt) 2011-08-16
HK1133875A1 (en) 2010-04-09
NL2000583A1 (nl) 2007-10-23
DOP2007000080A (es) 2007-11-15
GT200700035A (es) 2008-02-05
JP2009534368A (ja) 2009-09-24
AU2007242555B2 (en) 2010-12-16
CU20080194A7 (es) 2011-03-21
CY1111739T1 (el) 2015-10-07
EA014919B1 (ru) 2011-04-29
TW200808794A (en) 2008-02-16
CU23777B7 (es) 2012-02-15
CR10327A (es) 2008-10-21
ATE513831T1 (de) 2011-07-15
DK2013208T3 (da) 2011-08-15
PE20080192A1 (es) 2008-03-01
RS20080484A (sr) 2009-07-15
ECSP088803A (es) 2008-11-27
PL2013208T3 (pl) 2011-10-31
EP2013208A1 (en) 2009-01-14
CA2649775A1 (en) 2007-11-01
MX2008012456A (es) 2008-10-10
EP2013208B1 (en) 2011-06-22
SV2008003074A (es) 2010-01-12
WO2007122466A1 (en) 2007-11-01
IL194591A (en) 2012-07-31
AP2008004640A0 (en) 2008-10-31
MY148583A (en) 2013-04-30
MA30352B1 (fr) 2009-04-01
EA200801998A1 (ru) 2009-04-28
KR20080110930A (ko) 2008-12-19
ZA200808283B (en) 2009-11-25
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
JP4436892B2 (ja) 2010-03-24
US7902195B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
TNSN08408A1 (fr) PYRIDINE [3,4-b] PYRAZINONES
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
NL300929I2 (nl) Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2007135527A3 (en) Benzimidazolyl compounds
SE0401971D0 (sv) Piperidne derivatives
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY30500A1 (es) Compuestos de azabencimidazolilo
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
EA017278B9 (ru) Соединения азаиндазола и способы применения
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
IN2012DN03182A (enExample)
UA99787C2 (en) Lactams as beta secretase inhibitors
WO2010033198A3 (en) Analogs of indole-3-carbinol and their use as agents against infection
SE0401970D0 (sv) Novel compounds
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
TW200738698A (en) Organic compounds
WO2004046122A3 (en) Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
MA32290B1 (fr) Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives